Devices/drugs to remain under DG Sanco in newly approved EU Commission
This article was originally published in Clinica
Executive Summary
Oversight of medical device and drug policy in the EU is to remain with the European Commission’s health directorate (DG Sanco), and not with the industry directorate (DG ENTR). The news was announced just before the European Parliament today voted in favor of the new European Commission, which will be led by President Jean-Claude Juncker and officially begin work on 1 November. There were 423 votes for the new commission and its new college of commissioners, 209 votes against and 67 abstentions.
You may also be interested in...
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.
First Danish Notified Body Named Under EU's Medical Device Regulation
The EU now has a total of 45 notified bodies under the MDR.